General goal:
Most biopharmaceutical proteins contain protein-linked sugars (glycans), which are remodeled by GlycoDelete technology into small, homogeneous 'handles' on the protein, which introduce new functionality, either on their own or after coupling to other molecules. This GlycoDelete SBO consortium aims to exploit this disruptive glyco-engineering technology for the production and testing of a range of improved biopharmaceuticals, as the basis for a new spin-off company. The consortium consists of teams with leading expertise in glyco-biotechnology, bio-organic chemistry, in vivo imaging and experimental medicine.